echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Takeda and MD Anderson reach an agreement to develop car NK cell therapy derived from cord blood

    Takeda and MD Anderson reach an agreement to develop car NK cell therapy derived from cord blood

    • Last Update: 2019-11-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 5, Takeda Pharmaceutical Co., Ltd and MD Anderson Cancer Center announced an exclusive license agreement and research agreement to develop umbilical cord blood derived car NK cell therapy "armed" with IL-15 for B-cell malignancies and other cancers Under the agreement, Takeda will gain access to MD Anderson's car NK platform and have exclusive rights to up to four programs that have been commercialized, including car NK cell therapy for CD19 and car NK cell therapy for B-cell mature antigen (BCMA) Takeda and MD Anderson will also conduct research cooperation to further develop these car NK programs "Our vision is to develop a car NK cell therapy that patients can use on-site in outpatient clinics to improve the existing treatment, so that more patients can receive effective, rapid and minimally toxic treatment," said Katy rezvani, MD Takeda's expertise in hematological malignancies and plans to develop the next generation of cell therapy can help our team advance the development of car NK cell therapy " NK (natural killer) cells are a part of the innate immune system of human body, which can react quickly to various pathogens encountered in the body, and they are the normal cancer resistance reserve of the body, so they are called natural killer cells It plays a similar role with cytotoxic T cells in the acquired immune system But the difference between them is: generally, cytotoxic T cells need to detect the MHC on the surface of virus cells, which will cause the release of cytokines, leading to target cell lysis or apoptosis; NK cells can recognize these cells and carry out rapid immune response without antibody or MHC NK cells can kill MHC-I cells without activation These cells are usually harmful but cannot be found and destroyed by other immune cells In order to avoid injuring healthy cells, NK cells negatively regulate their activity by expressing KIRs (immunoglobulin (Ig) - like receptors), CD94 – NKG2 and mhci peptide When NK cells recognize the peptide presented by MHC as an autoantigen peptide, the inhibition signal is activated to prevent NK from killing healthy cells (Fig 1-A) Once tumor cells or other damaged cells down regulate the MHC elimination inhibition signal in order to escape the acquired immune pursuit, NK cells can kill the target cells through certain activation signals (Fig 1-B) Even if there is inhibition signal, NK cells can activate NK cells to kill target cells by activating strong activation signal pathway (Fig 1-C) NK cells directly activate ADCC function through IgG antibody enriched on the surface of tumor cells, killing tumor cells directly ADCC is also the main way NK cells kill target cells (Figure 1-D) Based on the characteristics of non limited, pan specific recognition, killing target cells and rapid response of NK cell MHC, scientists have developed car NK cell therapy, which enhances the ability of NK cell to target and kill tumor cells, which makes it more and more concerned and expected in the application of tumor immunotherapy In order to speed up the process of adoptive cell therapy (ACT), in the treatment of B-cell lymphoma, MD Anderson Cancer Center changed from the early cd19car-t cell treatment mode to car NK cell therapy which has stronger killing power to cancer cells and will not produce abnormal reaction after treatment, and thus obtained a mature act platform In June 2017, they induced and differentiated NK cells with cord blood, modified car NK cells with retroviral vector, inserted car to recognize CD19, and enhanced its ability to attack specific tumor cells with gene transfer (CD19 car increased the specificity of cell recognition for B-cell malignant tumors, while IL-15 enhanced car) The proliferation and survival of NK cells in vivo This cell therapy has been used to treat relapsed or drug-resistant chronic lymphoblastic leukemia (CLL), acute lymphoblastic leukemia (all) and non Hodgkin's lymphoma, and the trial has entered the clinical stage I and II The cancer center plans to use CD19 car n cell therapy in outpatient clinics in the future Since the birth of car cell therapy, it has attracted great attention of all major medical people at home and abroad Takeda pharmaceutical, headquartered in Osaka, Japan, is no exception In the past two years, the company has been seizing various opportunities to carry out cooperation on T-cell immunotherapy with major enterprises, and constantly promote the process of car cell therapy In May 2017, Takeda and gamma delta therapeutics announced a strategic partnership The aim of this cooperation is to develop a new T cell platform based on the unique characteristics of δ T cells in human tissues The two companies plan to use this novel platform to discover and develop new immunotherapies to treat a wide range of cancers, including solid tumors and autoimmune diseases In September 2017, shortly after the US Food and Drug Administration (FDA) approved kymeriah, the first car-t therapy company Novartis, Takeda signed an agreement with noele immune Biotechnology (noile), a biotech startup, to develop car-t therapy Takeda and noile have strengthened their relationship and exercised an option in the context of existing research cooperation It has obtained the exclusive authorization of nib-102 and nib-103 assets for the treatment of various solid tumor indications, and developed car-t cell therapy with noele using the company's proprietary "prime" (proliferation induction and migration enhancement) car-t platform Takeda will work with memorial Sloan Kettering Cancer Center (MSKCC) to discover and develop new chimeric antigen receptor T cell (car-t) products for the treatment of multiple myeloma, acute myeloid leukemia and other solid tumor indications This broad, multifaceted collaboration will be led by Dr Michel sadelain, a pioneer in car-t therapy, who is the director of MSKCC's cell engineering center and the scientific founder of Juno therapeutics, which was acquired by celgene for $9 billion In a third deal with crescendo biology, Takeda exercised its option to license humabody ® for oncology to evaluate humabody ® VHS for the development of new car-t therapies Takeda said the development would "take advantage of the unique properties of single domain tumor targeting conjugates as an alternative to traditional single chain variable fragment (scFv) methods." In July 2019, Takeda pharmaceutical company and CIRA (iPS cell research and Application Center) of Kyoto University announced that the first car-t therapy (Icart) based on IPSC (induced multifunctional stem cells) of the University was authorized to Takeda, and Takeda will carry out clinical development of the therapy In addition, Dr Shin Kaneko, CIRA, who is mainly responsible for the development of Icart, will continue to serve as Takeda's participation consultant for its subsequent clinical development and application The sixth cooperation is the agreement announced with MD Anderson on the development of umbilical cord blood derived car NK cell therapy "armed" with IL-15 for the treatment of B-cell malignant tumors and other cancers It's not hard to see that Takeda's impetus to the research and development of car cell therapy is very strong "We need to work quickly and purposefully because we intend to launch key research on CD19 car NK in 2021," said Andy, President of R & D at Takeda pharmaceutical In the future, the company is expected to bring more breakthroughs in car cell therapy.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.